AY4166 Phase III Long-term Study in Type 2 Diabetes Patients
Phase 3
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221882
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy
- HbA1c (NGSP) in the range of ≥ 6.9 to < 8.9 %
- postprandial plasma glucose 1 hour or 2hour after meal in the range of ≥ 200 mg/d
Exclusion Criteria
- Type 1 diabetes mellitus
- Patients with significant complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method